Pierre Charneau

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, Commercial Building & Real Estate, Manufacturing, Construction & Property, Health, Pharmaceutical, Oncology, Other Science, Other Manufacturing, Genetics, Science, Branches of biology, Bluebird bio, Psychological resilience, Viral vector, Biology, Biotechnology, Pierre Charneau

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.

Key Points: 
  • National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
  • Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebirds spin-off oncology cell therapy company that is expected to launch by the end of 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210728005511/en/
    The 125,000-square foot facility, located in Durham, North Carolina, is currently manufacturing lentiviral vector (LVV), a critical component for cell and gene therapies.
  • In consideration for the acquisition of the bRT facility upon the closing of the transaction, bluebird will receive $110 million from Resilience.

Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Biology, Virotherapy, Gene delivery, Applied genetics, Gene therapy, Molecular biology, Viral vector, Chimeric antigen receptor T cell, Lentivirus, Pierre Charneau, Oxford BioMedica

Lentigen is a leader in translating gene therapy products into the clinic, including design, construction and production of lentiviral vectors, from research through GMP manufacturing.

Key Points: 
  • Lentigen is a leader in translating gene therapy products into the clinic, including design, construction and production of lentiviral vectors, from research through GMP manufacturing.
  • As part of the agreement, Lentigen will reserve capacity in 2021 to manufacture, test and release GMP lentivirus to support and accelerate the development of Oncternals CAR-T cell therapy program.
  • Lentiviral vectors are an essential component in the CAR-T cell manufacturing process.
  • Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.